Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis

Claudia Fabiani, Jurgen Sota, Antonio Vitale, Giacomo Emmi, Lorenzo Vannozzi, Daniela Bacherini, Giuseppe Lopalco, Silvana Guerriero, Vincenzo Venerito, Ida Orlando, Rossella Franceschini, Fiorella Fusco, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini

Research output: Contribution to journalArticlepeer-review


© 2017, Taylor & Francis. All rights reserved. Purpose: To evaluate the 10-year drug retention rate of infliximab (IFX) in Behçet’s disease (BD)-related uveitis, the effect of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on drug survival and differences according to the lines of biologic treatment. Methods: Cumulative survival rates were studied using the Kaplan-Meier plot, while the Log-rank (Mantel-Cox) test was used to compare survival curves. Results: Forty patients (70 eyes) were eligible for analysis. The drug retention rates at 12-, 24-, 60- and 120-month follow-up were 89.03%, 86.16%, 75.66% and 47.11% respectively. No differences were identified according to the use of concomitant DMARDs (p = 0.20), while a statistically significant difference was observed in relation to the different lines of IFX treatment (p = 0.014). Visual acuity improved from baseline to the last follow-up visit (p = 0.047) and a corticosteroid-sparing effect was observed (p  < 0.0001). Conclusions: IFX retention rate in BD-uveitis is excellent and is not affected by concomitant DMARDs.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalOcular Immunology and Inflammation
Publication statusAccepted/In press - Nov 4 2017


  • Behçet’s disease
  • drug retention rate
  • infliximab
  • treatment
  • uveitis


Dive into the research topics of 'Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis'. Together they form a unique fingerprint.

Cite this